GlassScriptPhysician profile
Debora S Argetsinger
NPI 1376931717
$5,962.45
in general payments reported to CMS, 2019-2025
25 companies · $3,254 in 2025
The $3,254 reported for 2025 was more than what 97% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
See the full distribution for Gerontology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $41.83 · 2024: $2,667 · 2025: $3,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,023 · Food and Beverage: $2,583 · Education: $207 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,022.81 |
| Food and Beverage | $2,583.14 |
| Education | $206.50 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,327.56 | 2024-2025 | Infinity, Proclaim |
| Genzyme Corporation | $588.88 | 2024-2025 | |
| Abbvie INC. | $537.18 | 2024-2025 | |
| Emd Serono, INC. | $329.19 | 2024 | Mavenclad |
| Biogen, INC. | $150.00 | 2025 | Tysabri |
| Tg Therapeutics, INC. | $121.96 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $106.98 | 2024 | Zeposia |
| Novartis Pharmaceuticals Corporation | $102.61 | 2024-2025 | |
| Mdd US Operations, LLC | $100.85 | 2025 | |
| Neurelis, INC. | $80.64 | 2024-2025 | Valtoco |
| Lilly USA, LLC | $62.60 | 2023-2025 | Kisunla |
| Acadia Pharmaceuticals INC | $60.31 | 2024-2025 | Nuplazid |
| Celgene Corporation | $57.38 | 2024-2025 | Zeposia |
| Argenx US, INC. | $56.55 | 2024 | Vyvgart Hytrulo, Vyvgart |
| Pfizer INC. | $43.83 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $33.41 | 2025 | |
| Eisai INC. | $26.30 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.49 | 2023 | Entyvio |
| Genentech USA, INC. | $24.84 | 2025 | Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $24.61 | 2024 | Ultomiris |
| Medtronic, INC. | $24.35 | 2025 | Linq II |
| Teva Pharmaceuticals USA, INC. | $22.61 | 2024 | Austedo Xr |
| Kyowa Kirin, INC. | $20.42 | 2024 | Nourianz |
| Sk Life Science, INC. | $19.52 | 2024 | |
| Lundbeck LLC | $14.38 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debora Argetsinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.